Fig. 3
From: p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer
Inhibition of the p90RSK pathway with BI-D1870 reverses cisplatin resistance in HN30-R8 cells in vitro. (A and B) Cell proliferation assay at 72 h to determine EC50 values for BI-D1870 in the indicated cisplatin resistant cells and corresponding parental cell line. Representative graphs from one experiment are shown. (C) Table indicating average EC50 value for BI-1870. Statistical significance was calculated using Student’s t-test. *p < 0.05. (D) Viability of HN30-R8 cells treated with cisplatin and BI-D1870. Black asterisks compare the viability of cells with and without BI-D1870 within cisplatin treatments. Statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparison test. ***p < 0.0001. Red asterisks compare the viability of cells treated with BI-D1870 alone to cells treated with cisplatin and BI-D1870. Statistical significance was calculated using two-way ANOVA with Tukey’s multiple comparison test. ***p < 0.05